KCM
MED icon

Kendall Capital Management’s Medifast MED Stock Holding History

Kendall Capital Management’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,330
Closed -$319K – 215
2024
Q1 		$319K Sell
8,330
-725
-8% -$35.1K 0.11% 170
2023
Q4 		$609K Sell
9,055
-890
-9% -$62K 0.24% 120
2023
Q3 		$744K Sell
9,945
-1,920
-16% -$170K 0.33% 95
2023
Q2 		$1.09M Sell
11,865
-805
-6% -$71.7K 0.48% 69
2023
Q1 		$1.31M Sell
12,670
-115
-0.9% -$12.7K 0.63% 52
2022
Q4 		$1.48M Buy
12,785
+2,965
+30% +$345K 0.75% 41
2022
Q3 		$1.06M Buy
9,820
+1,210
+14% +$173K 0.62% 52
2022
Q2 		$1.55M Buy
8,610
+2,905
+51% +$520K 0.86% 37
2022
Q1 		$974K Buy
5,705
+1,975
+53% +$372K 0.47% 67
2021
Q4 		$781K Buy
+3,730
New +$771K 0.37% 86

Other funds holding MED

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Kendall Capital Management's MED Position: Q2 2024 in Review

Kendall Capital Management sold out of Medifast (MED) in Q2 2024, closing a stake of 8,330 shares — an estimated $319K sold.

Kendall Capital Management first reported a position in MED in Q4 2021 and held it in 10 quarters. The position peaked at $1.55M in Q2 2022. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

  • Kendall Capital Management reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
  • Kendall Capital Management sold 8,330 Medifast shares in Q2 2024, an estimated $319K.
  • Kendall Capital Management first reported a position in Medifast in Q4 2021 and held it in 10 quarters.
  • Kendall Capital Management's Medifast position peaked at $1.55M in Q2 2022.
  • 158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Kendall Capital Management's 13F filing for Q2 2024, filed 12 Aug 2024.